Caroline Seymour

Sandip P. Patel, MD, discusses existing and emerging immunotherapy approaches for patients with locally advanced and metastatic NSCLC.

Jing Ai, MD, discusses the treatment of patients with myelodysplastic syndrome.

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

Ryan W. Jacobs, MD, discusses the use of small molecule inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Shana Wingo, MD, discusses the surgical landscape in patients with newly diagnosed ovarian cancer.

Lauren C. Harshman, MD, discusses ongoing clinical trials examining the incorporation of immune therapies into practice.

Dennis R. Scribner Jr, MD, discusses the elements and evolution of treatment for patients with recurrent ovarian cancer.

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Rena D. Callahan, MD, discusses controversies in the management of early-stage HR-positive breast cancer and neoadjuvant trial designs for these patients.

Aashini Master, DO, discusses efforts to integrate nutrition and health into breast cancer survivorship.

Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.

Michael R. Grunwald, MD, discusses new and emerging agents in acute myeloid leukemia and acute lymphoblastic leukemia, as well as sequencing and toxicity challenges with these treatments.

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

Charles M. Rudin, MD, PhD, discusses ongoing developments with immunotherapy in patients with non–small cell lung cancer.

Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.

Mark G. Kris, MD, discusses the continued significance of chemotherapy in patients with NSCLC in the era of targeted agents and immunotherapy.

Reshma L. Mahtani, DO, discusses the use of adjuvant endocrine therapy in premenopausal breast cancers, specifically the use of ovarian function suppression and GnRH agonists.

Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.

Sara A. Hurvitz, MD, discusses the development of biosimilars and their potential use in the breast cancer field.

Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.

Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.

Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer.

Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.

Ashley A. Weiner, MD, PhD, discusses the expansions and limitations of radiotherapy in patients with non–small cell lung cancer and ongoing efforts to enhance administration and efficacy.

Laura M. Freedman, MD, discusses the impact of the updated NCCN guidelines on clinical applications of radiation therapy in patients with breast cancer.